Comparative proteomics of paired vocal fold and oral mucosa fibroblasts

Michael Karbienera,*, Barbara Darnhoferb,c,d, Marie-Therese Frische, Beate Rinnere, Ruth Birner-Gruenbergerb,c,d, and Markus Gugatschkaa

aDepartment of Phoniatics, ENT University Hospital, Medical University of Graz, Austria
bResearch Unit, Functional Proteomics and Metabolic Pathways, Institute of Pathology, Medical University of Graz, Austria
cOmics Center Graz, BioTechMed-Graz, Austria
dAustrian Centre of Industrial Biotechnology (ACIB), Austria
eCore Facility Alternative Biomodels and Preclinical Imaging, Division of Biomedical Research, Medical University of Graz, Austria

Abstract

Injuries of the vocal folds frequently heal with scar formation, which can have lifelong detrimental impact on voice quality. Current treatments to prevent or resolve scars of the vocal fold mucosa are highly unsatisfactory. In contrast, the adjacent oral mucosa is mostly resistant to scarring. These differences in healing tendency might relate to distinct properties of the fibroblasts populating oral and vocal fold mucosae. We thus established the in vitro cultivation of paired, near-primary vocal fold fibroblasts (VFF) and oral mucosa fibroblasts (OMF) to perform a basic cellular characterization and comparative cellular proteomics. VFF were significantly larger than OMF, proliferated more slowly, and exhibited a sustained TGF-β1-induced elevation of pro-fibrotic interleukin 6. Cluster analysis of the proteomic data revealed distinct protein repertoires specific for VFF and OMF. Further, VFF displayed a broader protein spectrum, particularly a more sophisticated array of factors constituting and modifying the extracellular matrix. Conversely, subsets of OMF-enriched proteins were linked to cellular proliferation, nuclear events, and protection against oxidative stress. Altogether, this study supports the notion that fibroblasts sensitively adapt to the functional peculiarities of their respective anatomical location and presents several molecular targets for further investigation in the context of vocal fold wound healing.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

*Corresponding author at: Department of Phoniatics, ENT University Hospital, Medical University of Graz, Auenbruggerplatz 26, 8036 Graz, Austria. michael.karbiener@medunigraz.at (M. Karbiener).

Author contributions
MK conceived and designed the study, collected data, performed data analysis and interpretation, and wrote the manuscript. BD and MTF collected data and performed data analysis and interpretation. BR and RBG: conceived and designed experiments, analyzed data and contributed to manuscript writing. MG conceived and designed the study, provided financial support and contributed to manuscript writing. All authors have given approval to the final version of the manuscript.

Additional information
The authors declare no competing financial interest.

Transparency document
The transparency document associated with this article can be found, in online version.
Biological significance—Mammalian vocal folds are a unique but delicate tissue. A considerable fraction of people is affected by voice problems, yet many of the underlying vocal fold pathologies are sparsely understood at the molecular level. One such pathology is vocal fold scarring - the tendency of vocal fold injuries to heal with scar formation -, which represents a clinical problem with highly suboptimal treatment modalities. This study employed proteomics to obtain comprehensive insight into the protein repertoire of vocal fold fibroblasts, which are the cells that predominantly synthesize the extracellular matrix in both physiological and pathophysiological conditions. Protein profiles were compared to paired fibroblasts from the oral mucosa, a neighboring tissue that is remarkably resistant to scarring. Bioinformatic analyses of the data revealed a number of pathways as well as single proteins (e.g. ECM-remodeling factors, transcription factors, enzymes) that were significantly different between the two fibroblast types. Thereby, this study has revealed novel interesting molecular targets which can be analyzed in the future for their impact on vocal fold wound healing.

Keywords
Laryngology; Vocal folds; Oral mucosa; Fibroblasts; Fibrosis; Wound healing

1 Introduction
Modern society is strongly dependent on successful communication skills, making a healthy voice more important than ever before. Voice production is inextricably linked with physiological vibration of the vocal folds, which in turn is enabled by the finely tuned actions of laryngeal muscles, as well as by the sophisticated microarchitecture of the vocal fold mucosa (VFM) [1]. Detrimental changes of this delicate structure lead to pathological vibratory behavior and thus are often linked to voice problems, such as hoarseness and an unstable voice [2]. Indeed, the majority of patients seeking treatment for voice disorders present with organic vocal fold (VF) changes [3]. Scarring of the VF (due to chemical or physical traumata, e.g. surgery of the VF) is one prominent VF pathology that is characterized by a suboptimal reconstitution of the VF lamina propria by its main resident cells, the VF fibroblasts (VFF) [4]. Presence of a VF scar can be accompanied by a lifelong impairment of voice quality, yet current treatment modalities are largely unsatisfactory. Next-generation medical strategies could comprise transplantation of ex vivo generated VFM [5,6] or pharmacological approaches, i.e. the application of anti-fibrotic drugs [7,8] in order to resolve VF scars or even prevent their development. However, there is still a marked paucity of knowledge about VFM cells, which hampers the development of novel clinical applications.

In contrast to the VFM, the oral mucosa (OM) is endowed with a markedly scar-resistant phenotype. Studies that compared healing of oral wounds and scar-prone adult dermis have suggested several factors that contribute to superior healing of the OM [9]. These findings are largely in agreement with comparisons between adult dermis and fetal dermis, the latter being one of the most intensively studied tissues capable of scarless healing [10,11]. In general, wounds of scar-resistant tissues were found to contain reduced pro-inflammatory and pro-fibrotic mediators, lower blood vessel density, as well as fast-proliferating epithelial cells and fibroblasts [9,12]. Despite the evident risk of VF injuries to heal with scar
formation, few of these and other healing-related features have been investigated in the VFM in a comparative manner. Experiments in rats have identified significant differences in the expression of the cytokines transforming growth factor beta 1 (TGF-β1) and transforming growth factor beta 3 (TGF-β3) in VFM versus OM and skin, which likely are related to the distinct healing tendencies of these tissues [13]. Further, a recent study has for the first time shed light on global transcriptional changes in the VFM after injury [14]. While the classical division of wound healing into the three phases inflammation, proliferation, and remodeling might in principle also apply to the VF, the study’s results suggest a considerable overlap of the cell division/proliferation and inflammatory activity phases. Further, previously undescribed mRNAs with dynamic expression during VF wound healing were identified [14], some of which could eventually become therapeutic targets.

An alternative way to better define the weak spots of VF wound healing is the direct comparison of VF cells to cells arising from tissues with superior healing properties, which is the focus of the present study. Although VF cells have been benchmarked against other cells with respect to small sets of genes/proteins of interest (e.g. related to the extracellular matrix (ECM) [15] or surface antigens [16,17]), it should be noted that, to date, no comprehensive comparison between a distinct VF cell type and its counterpart in other tissues has been performed. To close this gap, we first established cell cultures of VFM and OM to obtain paired, near-primary populations of the fibroblasts homing to the respective tissue. Second, we performed a basic cellular characterization of the fibroblast populations, covering the aspects of marker gene expression, size, morphology, proliferation, migration, 3D culture characteristics and response to a pro-fibrotic stimulus. Third, fibroblast pairs were subjected to label-free quantitative proteomics to provide a comprehensive comparison between cells of the VFM and the OM, including significantly overrepresented gene sets and corresponding pathways.

2 Materials and methods

2.1 Standard 2D cell culture

Paired tissue samples from sheep VFM and OM (Vestibulum oris) were obtained from the local slaughterhouse (approximately 1 h post mortem) and transported to the laboratory in Dulbecco's Modified Eagle's Medium (DMEM; Life Technologies, Carlsbad, CA) supplemented with 1× l- Glutamine–Penicillin–Streptomycin solution (GPS; Sigma-Aldrich, St. Louis, MO). Subsequent steps were performed in a laminar flow hood. For decontamination, tissues were incubated in DMEM supplemented with 10× GPS at room temperature for 10 min, followed by dipping in 70% Ethanol for 10 s and extensive rinsing in Phosphate buffered saline (PBS, Life Technologies). VF and OM tissues were then pinned on a sterile cork plate with the epithelium downwards. This enabled the preparation of small tissue pieces (approximately 2 mm × 2 mm × 2 mm) consisting mainly of connective tissue and only minimal residual epithelium. Tissue pieces were placed in 12 well plates (Greiner Bio-One, Kremsmünster, Austria) and allowed to adhere by 5–10 min of incubation (without lid). Finally, tissue pieces were carefully overlaid with serum-reduced growth medium (GM), consisting of DMEM/F12 Nutrient Mix (Life Technologies) (3:1), 5% Fetal Bovine Serum (FBS; Biochrom, Berlin, Germany), 1× Insulin-Transferrin-Selenium (Life
Technologies), 200 nM 3,3′,5-Triiodo-l-thyronine, 100 ng/mL human Insulin-like Growth Factor-I, 12.5 ng/mL human Fibroblast growth factor-2 (all Sigma), and 100 μg/mL Normocin (Invivogen, San Diego, CA). Tissue pieces were cultivated in a humidified atmosphere at 37 °C and 5% CO₂ and GM was partially (50% v/v) replaced by fresh GM every 2–4 days. After robust outgrowth of fibroblastoid cells from adherent tissue pieces (but before the appearance of a confluent cell layer) the first passaging was performed using 0.5% trypsin (Sigma). Cells were subsequently passaged every 3–4 days at passaging ratios between 1:2 and 1:8. For downstream analyses, seeding of cells into culture plates at defined cell densities was based on manual counting of trypsinized cell suspensions using a hemocytometer and subsequent calculation of cell concentrations.

2.2 Real time cell growth assay

Cell proliferation was measured using the xCELLigence (OLS OMNI Life Science Bremen, Germany) Real-Time Cellular Analysis system. Briefly, the background impedance was measured following the addition of 100 μL of GM to the 16-well E-plates (OLS). Cell suspensions containing 5000 cells in 100 μL GM were seeded into the wells and attachment and proliferation were monitored using the xCELLigence Real-Time Cellular Analysis system. Impedance changes expressed as cell index (CI) were automatically calculated and correlated with cell growth over a period of 100 h.

2.3 3D spheroid cell culture

20,000 cells resuspended in GM were seeded in hanging drops (20 μL) under the lids (Lactan, Graz, Austria) of cell culture plates. The dish was carefully inverted to keep the drops intact. 10 mL PBS were added to the bottom of the dish to prevent dehydration. Drops were cultured at 37 °C in 5% CO₂ without medium change for up to three days. To investigate attachment and cell spreading, spheroids were subsequently pipetted into 12 well plates with 1 mL GM per well.

2.4 2D migration assay

Pairs of VFF and oral mucosa fibroblasts (OMF) with similar passage numbers were seeded into 2-chamber silicone inserts which were placed in a 24 well plate (ibidi, Martinsried, Germany). Depending on preliminary experiments, 20,000–30,000 cells resuspended in 70 μL GM were pipetted into each chamber and incubated overnight, which resulted in confluent cell layers. Subsequently, silicone inserts were removed with sterile forceps, cells were washed 3 times with PBS and 1 mL of standard medium (SM), consisting of DMEM/F12 Nutrient mix (3:1) supplemented with 5% FBS and 100 μg/mL Normocin, was added per well. Closure of the 500 μm gap between the 2 regions of cells was monitored using a Cell-IQ system (Chipman Technologies, Tampere, Finland) with automated phase contrast imaging (4–6 regions per well) performed every 30 min over a period of 72 h. Semi-automatic segmentation of the image series and quantitative analysis was performed using the Cell-IQ software. For each cell type, at least 3 wells (assayed in parallel) were averaged as technical replicates.
2.5 Reverse transcription quantitative real-time PCR (RT-qPCR)

Cells were seeded in GM into 12 well plates (Greiner) at 5000–10,000 cells/cm². After 4 days, the medium was changed to SM. The next day, medium was again changed to SM ± 5 ng/mL TGF-β1 (R&D Systems, Minneapolis, MN). Cells were lysed in 700 μL QIAzol after 24 h and 72 h. RNA isolation was performed using the miRNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's protocol. Concentrations of RNA samples were determined on a NanoDrop 2000c UV–Vis spectrophotometer (Thermo Scientific, Waltham, MA) and 1 μg total RNA was used as input for cDNA synthesis using the QuantiTect Reverse Transcription kit (Qiagen) according to the manufacturer's instructions. For RT-qPCR, cDNA samples were diluted with nuclease-free water to 2.5 ng RNA/μL, and 4 μL of diluted solutions were combined with 5 μL GoTaq® qPCR Master Mix (Promega, Mannheim, Germany) and 1 μL of the respective primer pair mix (each primer: 2 μM) in 384 well plates. Sequences of primers are listed in Supplemental Table 1 in the supporting information (SI). Each combination of cDNA and primer pair was assayed in technical triplicates. RT-qPCR was performed on a LightCycler® 480 system (Roche, Vienna, Austria) using the following program: 2 min/95 °C (denaturation), 45 cycles of 10 s/95 °C and 1 min/60 °C (amplification), ramping at 2.5 °C/min from 55 °C to 95 °C (melting curve analysis). C_T values were calculated using the AbsQuant/2nd Derivative Max method of the LightCycler® 480 software. Relative quantification of expression levels of the genes of interest was further performed according to the 2^−ΔΔC_T method [18] using UXT as internal reference RNA.

2.6 LC-MS/MS analysis

Pairs of VFF and OMF with similar passage numbers were seeded into T75 cell culture flasks (Greiner). At ~50% optical confluence, old medium was removed and cells were washed twice with PBS before addition of fresh DMEM/F12 Nutrient Mix (3:1). After incubation for 6 h, cells were trypsinized and the resulting cell suspension was centrifuged at 170 ×g for 7 min. Supernatants were discarded and cell pellets were resuspended in PBS, followed by determination of cell concentration and centrifugation as before. Supernatants were thoroughly removed, cell pellets were snap frozen in liquid nitrogen and stored at − 80 °C. One million cells were lysed in 100 μL lysis buffer (100 mM Tris pH 8.0, 10 mM TCEP, 40 mM 2-chloroacetamide and 1% SDS) by sonication for 2 min on ice. The lysates were heat denatured for 10 min at 90 °C. The supernatants were collected after removal of cell debris by centrifugation at 1000 ×g for 10 min at room temperature. Protein was determined by BCA-RAC assay (Thermo Scientific). Protein patterns were visualized by SDS-PAGE on 4–12% NuPAGE Bis-Tris gels (Thermo Fisher Scientific), Krypton (Thermo Fisher Scientific) staining and fluorescence laser scanning on a Bio-Rad FX Pro Plus Imager. For LC-MS/MS analysis 20 μg protein were subjected to filter aided sample preparation as described previously [19] with minor modifications using 3 kD cut off ultracentrifugation filters (Millipore). Buffer was exchanged three times with 8 M Urea, 100 mM TrisHCl, pH 8.0. The samples were predigested with rLysC (Promega, enzyme/protein 1:100) for 4 h at 37 °C, diluted to 2 M Urea with 100 mM ammonium bicarbonate and digested with trypsin (Promega, enzyme/protein 1:50) overnight. Peptides were collected by centrifugation at 14000 ×g for 45 min at room temperature. Samples were acidified with formic acid (final concentration of 0.1%). 500 ng protein digest of each sample yielding
similar total ion chromatograms (cf. Supplemental Fig. S1 in the SI) were injected and analyzed by nano-HPLC (Dionex Ultimate 3000) equipped with a C18, 5 μm, 100 Å, 5 × 0.3 mm, enrichment column and an Acclaim PepMap RSLC nanocolumn (C18, 2 μm, 100 Å, 500 × 0.075 mm) (all Thermo Fisher Scientific). Samples were concentrated on the enrichment column for 2 min at a flow rate of 5 μL/min with 0.1% heptafluorobutyric acid as isocratic solvent. Separation was carried out on the nanocolumn at a flow rate of 300 nL/min at 60 °C using the following gradient, where solvent A is 0.1% formic acid in water and solvent B is acetonitrile containing 0.1% formic acid: 0–6 min: 4% B; 6–150 min: 4–25% B; 150–155 min: 25–95% B, 155–165 min: 95% B; 165–165.1 min: 4% B; 165.1–180 min: 4% B. The maXis II ETD mass spectrometer (Bruker, Vienna, Austria) was operated with the captive source in positive mode with following settings: peptide fragmentation: CID, mass range: 200–2000 m/z, 2 Hz, capillary 1300 V, dry gas flow 3 L/min with 150 °C, nanoBooster 0.2 bar, precursor acquisition control top17.

2.7 Processing of LC-MS/MS data

The LC-MS/MS data were analyzed by the Data analysis software (Bruker), using the Sum Peak algorithm, and by MaxQuant by searching the public Uniprot database with taxonomy Ovis aries (downloaded on 13.06.2016, 13,148,561 residues, 27,448 sequences) and common contaminants. Carbamidomethylation on Cys was entered as fixed modification, oxidation on methionine as variable modification. Detailed search criteria were used as follows: trypsin, max. missed cleavage sites: 2; search mode: MS/MS ion search with decoy database search included; precursor mass tolerance ± 0.006 Da; product mass tolerance ± 40 ppm; acceptance parameters for identification: 1% PSM false discovery rate (FDR); 1% protein FDR. In addition a label free quantitation was performed using MaxQuant [20] requiring a minimum of 2 ratio counts of quantified razor and unique peptides. Total LFQ intensities of individual samples were as follows: VFF.BR1: 8.615.297.702; OMF.BR1: 9.078.542.438; VFF.BR2: 8.810.529.124; OMF.BR2: 8.819.990.495; VFF.BR3: 8.697.640.277; OMF.BR3: 9.160.585.501; VFF.BR4: 8.713.845.133; OMF.BR4: 8.890.439.610. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE [21] partner repository with the dataset identifier PXD005106. Further processing, data visualization, and statistical testing were performed with R (www.r-project.org). Briefly, identified common contaminant peptides were removed, and UniProtKB AC/IDs of the remaining hits were mapped to their respective gene symbols using the “Retrieve/ID mapping” function of www.uniprot.org. Spectra that were associated to different gene symbols were reduced to a single gene symbol based on the following criteria: (i) highest number of peptide counts (razor + unique); (ii) highest sequence coverage. Hierarchical Clustering was performed using the “complete linkage” method (hclust function of the R stats package). Gene Ontology (GO) term over-representation analysis was performed using the “Gene List Analysis” tool [22] from www.pantherdb.org with default settings. For proteins identified in both cell types, log2-transformed fold changes of label-free quantification (LFQ) intensity values were calculated for each VFF-OMF pair (pFC). Proteins were filtered for differential abundance (|mean(pFC)| > 0.58) and a paired t-test was conducted for hits where 3–4 pFC could be calculated, followed by applying the Benjamini-Hochberg correction for multiple testing. Gene Set Enrichment Analysis (GSEA) [23,24] was conducted using the javaGSEA desktop.
application with preset values of gene set sizes. Gene sets with a FDR-corrected p-value (FDR-q) < 0.1 were considered as significantly enriched.

3 Results and discussion

3.1 Establishment of paired VFF and OMF populations from sheep

As every surgical procedure on the VF bears the risk of scar development and thus lifelong voice disorder (dysphonia), obtaining non-pathological VFM samples from humans is rarely feasible. To circumvent this problem, we used sheep as a source of VFM as well as OM. This animal model has previously been demonstrated to be comparable to the human VF with respect to anatomical dimensions, phonation indices, and tissue histochemistry [25]. Outgrowth of fibroblastoid cells from VFM and OM tissue pieces started two to seven days after start of incubation in GM (Supplemental Fig. S2A in the SI). Occasionally, these primary cultures also contained cells with epithelial or endothelial morphology (Supplemental Fig. S2BC in the SI); however, these cells disappeared after the first passages. Further, expression of marker genes for skeletal muscle (ACTN3), epithelium (CDH1), and endothelial cells (VWF) was either close to background, or undetectable at passages 4–6 (Supplemental Fig. S2D in the SI). Thus, sufficiently pure populations of paired VFF and OMF could be successfully established from the corresponding sheep tissues. These near-primary cells were used for subsequent analyses.

3.2 Basic cellular characterization of paired VFF and OMF

Under standard cell culture conditions, VFF had a more elongated shape and were significantly larger than OMF (Fig. 1AB). Proliferation assays revealed that OMF exhibited faster growth than VFF (Fig. 1C), which was in line (i) with previous studies comparing human adult dermal fibroblasts and OMF [26]; and (ii) with the fact that passaging of OMF had to be performed at higher split ratios to prevent the formation of a confluent cell layer. Both cell types could be cultivated in a three-dimensional setting, yet with morphological differences: while VFF-derived spheroids appeared rather encapsulated, spheroid boundaries were less defined for OM-derived constructs. Correspondingly, OMF started to spread from the spheroid earlier than VFF (Fig. 1D; Supplemental Fig. S3 in the SI). Analysis of cell migration in a 2D migration assay revealed that two OMF populations had faster migratory characteristics than the respective VFF; however no cell-specific differences in migration could be measured for the other biological replicates (Supplemental Fig. S4 in the SI). TGF-β1 is a well-known pro-inflammatory cytokine that has been identified in various wounds (including VF wounds) [27] and that is also implicated in fibrosis in many tissues, e.g. via promoting myofibroblast differentiation as well as the expression of other pro-inflammatory mediators [28,29]. Twenty-four hours after exposure to TGF-β1 we identified a significant increase in the levels of the myofibroblast marker alpha smooth muscle actin (α-SMA, ACTA2) in OMF and a similar trend in VFF (Fig. 2A, left panels). For both cell types, significantly higher α-SMA mRNA levels were measured 72 h after TGF-β1 treatment (Fig. 2A, right panels). Thus, although we could confirm the classical induction of α-SMA by TGF-β1 for our in vitro models, the results are distinct from previous reports describing a decreased responsiveness for OMF [30]. Interleukin 6 (IL6) has been identified as a cytokine favoring scar development [31]. While TGF-β1 promoted a long-lasting significant increase
of IL6 in VFF, this effect was not observed for OMF, where IL6 expression had returned to baseline levels after 72 h (Fig. 2B). It can therefore be hypothesized that successful VF wound healing might be hampered at least partly due to the prolonged IL6 production of VFF, as opposed to a more short-lived response in the OM. Hyaluronic acid (HA) is an important component of the physiological VF ECM [32,33]. We therefore analyzed the expression of hyaluronan synthases, the key enzymes in HA biosynthesis. We found HAS1-3 to be expressed in all cell populations, yet only HAS1 mRNA to be significantly induced in VFF 24 h after TGF-β1 exposure (Supplemental Fig. S5 in the SI). Collectively, the basic cellular characterization of our newly established fibroblast populations revealed several phenotypical differences prompting a more comprehensive comparison of their repertoire of expressed proteins.

### 3.3 Comparison of VFF and OMF proteomes

As a first qualitative analysis, we separated VFF- and OMF-derived protein lysates by SDS-PAGE. Subsequent protein staining revealed highly similar band patterns within the four biological replicates of each cell type (Supplemental Fig. S6 in the SI). We therefore proceeded with trypsin digestion of the samples and subjected the resulting peptides to LC-MS/MS analysis. Altogether, 1609 unique proteins with association to a known gene were confidently identified (Supplemental Table S2 in the SI; cf. Materials and Methods). Of these, 53% (858 proteins) were detected in both VFF and OMF, while 35% (564 proteins) were found only in biological replicates of VFF and 12% (187 proteins) were identified only in biological replicates of OMF (Fig. 3A). In line with these overall values, the number of detected proteins was higher in every VFF biological replicate compared to the respective OMF pair (Fig. 3B). To further estimate congruencies in the protein repertoire, we performed pairwise comparisons of samples. The resultant average “overlap index” (i.e. the fraction of proteins detected in both samples, normalized to the total number of proteins detected in the respective combination) was 0.571 for comparisons across the two distinct cell types; while it was slightly higher (0.586 for VFF; 0.623 for OMF) for comparisons within the same cell type (Supplemental Fig. S7 in the SI). In order to obtain subsets of high-confidence hits, we filtered the total data for proteins that were repeatedly detected in independent samples. Interestingly, unsupervised clustering of the resulting data clearly distinguished the two fibroblast types (Fig. 3C). Collectively, these results revealed that protein profiles exist which are specific for VFF and OMF, respectively. This is in line with a previous study that found site-specific gene expression profiles of human adult dermal fibroblasts [34]. It also supports the notion that, although basic traits of distinct fibroblast populations might be similar, adaptations of the “fibroblast phenotype” meeting the functional peculiarities of the respective anatomical location exist.

### 3.4 Proteins with differential abundance

We next focused on the subset of 45 proteins that were reliably (i.e., present in 3–4 biological replicates) detected in VFF, yet never in OMF (“VFF-specific”; Fig. 4A). In line with cells being the starting material of our analysis, the general GO terms “cell”, “cell part”, “intracellular”, “intracellular part”, and “cytoplasmic part” were significantly overrepresented. Interestingly, also GO terms relating to the extracellular space and vesicles exhibited significant overrepresentation; the subset of corresponding proteins included the
alpha 2 chain of fibrillar collagen type I (COL1A2), the alpha 1 chain of the fibril-associated
collagen type 12 (COL12A1), enzymes responsible for collagen maturation (prolyl 4-
hydroxylase subunit alpha 1 (P4HA1), procollagen-lysine,2-oxoglutarate 5-dioxygenase 2
(PLD2)), as well as proteins involved in ER-Golgi and vesicular trafficking (SEC23A,
SEC23IP, FLOT2, ATP6V1E1). Further, also the GO terms “anchoring junction” and
“adherens junction” were significantly overrepresented due to the presence of several actin-
binding and -remodeling proteins (ITGA6, CNN1, DOCK7, SWAP70). Thymosin beta 4
(THYMB4X) is a critical regulator of F-actin assembly [35] and was the most abundant
VFF-specific protein in our screen. THYMB4X is also present in blood and wound fluid
[36], and has been described to block expression of pro-fibrotic genes [37] and accelerate
dermal wound healing [38]. With respect to the scarless healing properties of OM, it was
therefore surprising that we did not detect synthesis of THYMB4X by OMF. As for VF
wounds, THYMB4X mRNA showed a non-significant increase in the early phase of wound
healing in rat (analysis of publicly available microarray data (Gene Expression Omnibus;
GSE62204) from [14]). However, studies investigating a potential anti-fibrotic action of
THYMB4X in VF wound healing have not been performed to date. Unexpectedly, we
identified fibroblast growth factor 2 (FGF2), well-known for its mitogenic and angiogenic
activities [39,40], as another VFF-specific protein. FGF2 accelerates wound healing [41] and
has recently been shown to ameliorate VF scarring [42], possibly via reshaping the synthesis
of ECM components by VFF [43]. Our result thereby implies that (i) the faster growth of
OMF might be due to other factors than FGF2, and that (ii) the amount of FGF2 produced
by VFF in vivo might be too limited to enable scarless wound healing of the VF.

The converse subset of proteins that were reliably detected in OMF, but never in VFF
(“OMF-specific”) was considerably smaller (9 proteins) and thus, the only significantly
enriched GO term was “protein kinase B binding” (Fig. 4B). The corresponding proteins
were Girdin (CCDC88A), which interacts with actin, is activated by Akt/Protein kinase B
(PKB) and promotes DNA synthesis and cell motility [44,45], as well as adaptor protein
containing pleckstrin homology domain, phosphotyrosine binding domain and leucine
zipper motif (APPL1), a multidomain protein that mediates insulin as well as adiponectin
signaling [46]. Notably, the beneficial effects of several growth factors and small molecule
pharmacological agents in dermal wound healing (or specifically on dermal fibroblasts) have
been linked to activation of Akt/PKB signaling [47–50]. In addition, protective effects of
adiponectin have recently been demonstrated in lung fibrosis and might be mediated at least
partly by direct action on the resident fibroblasts [51]. In conjunction with our results, these
findings imply the future evaluation of pharmacological approaches involving Akt/PKB
activation and/or adiponectin in VF wounds.

Among the large subset of proteins that were detected in both cell types (Fig. 3C), we aimed
to select those that exhibited a significantly differential abundance (cf. Experimental
Procedures). Twenty such proteins were identified (Fig. 5), corresponding to ~4% of the
total of proteins that were reliably detected in both cell types; this proportion was similar as
in a recent study that compared gingival and dermal fibroblasts [52]. Candidates classified as
VFF-enriched comprised again actin-binding proteins such as nexilin F-actin binding protein
(NEXN), actinin alpha 1 (ACTN1), and cysteine and glycine rich protein 1 (CSRP1), which
has also been described as a critical transcriptional coregulator in smooth muscle cell
differentiation [53]. Conversely, candidates classified as OMF-enriched comprised several proteins with an established protective function against oxidative stress (glucose-6-phosphate dehydrogenase (G6PD), peroxiredoxin (PRDX1), transaldolase 1 (TALDO1)) and DNA damage (replication protein 1 (RPA1)). It can therefore be speculated that the superior wound healing of the OM might be partially due to a superior ensemble of stress-protective mechanisms in OMF. Indeed, the premature senescence of dermal fibroblasts from chronic wounds has been proposed to be due to a reduced ability to cope with oxidative stress [54]. Conversely, favorable effects of antioxidative agents have already been demonstrated for lung fibroblasts [55]. As reactive oxygen species are also known to be heavily induced in the early phase of VF wound healing [56], assessing the potential of antioxidative agents in VF injury is a promising future prospect. In analogy to the analysis of VFF- and OMF-specific protein sets, we also subjected the significantly VFF- or OMF-enriched protein sets to overrepresentation analysis. While no GO term was significantly overrepresented within the VFF-enriched set, the GO term “cytoskeleton” was significantly overrepresented within the OMF-enriched set. The subset of corresponding proteins included the two non-motor actin binding proteins Plectin (PLEC) and Coronin-1C (CORO1C). As these proteins also interact with intermediate filaments and microtubules [57,58], this result might reflect the distinct mechanical stresses implied on fibroblasts in OM versus VF.

3.5 Gene set enrichment analysis

We eventually subjected the entire dataset of reliably detected proteins to GSEA in order to identify biological categories that are most distinct between the two investigated fibroblast types. In total, eight gene sets were found to be significantly VFF-enriched (Table 1). Interestingly, these included gene sets of the “matrisome”, which was recently defined (based on a combination of in silico and experimental approaches) as the ensemble of architectural ECM proteins and associated proteins [59]. Further, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways related to cell-cell (tight junction) and cell-ECM (focal adhesion) interactions were also identified, as was a hallmark gene set defining epithelial to mesenchymal transition. Collectively, these results likely reflect the necessity of VFF to adapt to an environment of exceptional mechanical forces, i.e. the periodic vibration due to phonation events. It may be further postulated that the larger repertoire of ECM proteins produced by VFF is a prerequisite for the sophisticated structure of the VF lamina propria, as opposed to the less complex connective tissue layer of the OM. Such an inherent disproportion in the fibroblasts’ ECM-synthesizing abilities could partially explain the suboptimal results that have been achieved in the past when using autologous oral mucosa grafts as a surrogate structure for resected VF [2,60]. Procollagen C-endopeptidase enhancer (PCOLCE) was found as one of the VFF-enriched proteins contributing to the “matrisome” signature. As PCOLCE promotes the maturation of fibrillar procollagens into mature collagen fibers [61,62], future studies in which the function of this enzyme is antagonized could be of particular interest in the context of VF wound healing. Likewise, antagonism of PLOD2, a “matrisome” component that was identified as VFF-specific (Fig. 4A), might be a promising therapeutic approach, as the collagen cross-linking action of this enzyme is a key feature of fibrosis [63]. GSEA further revealed that potential direct targets of the miR-30 family of microRNAs were significantly enriched in the VFF proteome. We therefore queried miRTarBase, a compendium of experimentally validated miRNA-mRNA
interactions [64], and found that indeed 9 of the 15 proteins constituting the respective core enrichment (Table 1) have been validated as direct miR-30 targets. It would be interesting to analyze in the future whether miR-30 family members are indeed more abundant in OMF versus VFF, and if so, whether increasing miR-30 microRNAs in VFF might convey anti-fibrotic properties, as recently described for hepatic stellate cells [65] as well as for an in vitro model of kidney fibrosis [66].

GSEA also revealed that 20 gene sets were significantly enriched in OMF versus VFF (Table 2), a conspicuously larger number than the eight gene sets identified as VFF-enriched. This discrepancy is surprising given the clearly smaller repertoire of proteins expressed by OMF (Fig. 3). A possible explanation could be that molecular characterization of cells from the VF has been performed in less depth so far. Notably, a considerable fraction of OMF-enriched gene sets was related to the nucleus and biological processes within this compartment, most importantly processing of RNA. This finding is in line with the significant upregulation of two proteins constituting the nuclear lamina, lamin A/C (LMNA) and lamin B1 (LMNB1; Fig. 5). However, it is also partly surprising as e.g. upregulation of mRNA splicing would intuitively suggest a greater divergence in the OMF protein fingerprint, which is not the case. Alternatively, it can be hypothesized that OMF express a more sophisticated array of non-coding RNAs, which are likewise often subjected to ribonucleoprotein-dependent processing/maturation steps. Future comparative studies employing state-of-the-art RNA sequencing techniques should shed light on this issue.

Another interesting finding was the significant enrichment of the GO term “cell proliferation”, which is in line with the faster growth characteristics of OMF (Fig. 1C). This result was corroborated by the significant enrichment of two hallmark gene sets categorized as targets of the transcription factors MYC and E2F, both implicated in cell cycle progression [67]. In the case of E2F, further evidence is provided as several OMF-enriched proteins harbor consensus binding sites for the E2F transcription factor family in their promoter-associated regions. It is thus tempting to speculate that the OMF’s fast-proliferating nature is at least partly founded in transcriptional activities of distinct E2F isoforms, as previously described for other fibroblast types [68,69].

4 Conclusion

We have introduced near-primary fibroblasts from sheep VFM and OM as two novel in vitro models for the basic study of (patho)physiological aspects related to the respective tissue. This is especially important in the realm of laryngology, as in most instances ethical considerations prohibit the acquisition of VF biopsies from healthy humans. We further provide the first comprehensive proteomic comparison of VFF with another cell type, i.e. OMF, realized in a paired experimental design that precludes any identified difference being the result of genetic variation. Our proteome study has revealed that VFF and OMF are indeed distinct cell types, with VFF having a broader spectrum of expressed proteins, particularly a more sophisticated array of factors constituting and modifying the ECM. Last, comparative analyses of the VFF and OMF protein fingerprints have brought to light several interesting molecular pathways that could be utilized to tackle the problem of VF scarring from unprecedented angles.
Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the Austrian Science Fund (FWF) project J 3661 and the City of Graz (Sub A16 – 89 – 2015). The authors would like to thank Rudolf Sauseng and co-workers for providing sheep tissues. The authors further wish to thank Markus Absenger-Novak, Stefan Spoerk, Anita Leitner and Katharina Meditz for excellent technical support.

References

[1]. Titze I, Riede T, Mau T. Predicting achievable fundamental frequency ranges in vocalization across species. PLoS Comput Biol. 2016; 12:e1004907.doi: 10.1371/journal.pcbi.1004907 [PubMed: 27309543]

[2]. Friedrich G, Dikkers FG, Arens C, Remacle M, Hess M, Giovannini A, Duflo S, Hantzakis A, Bachy V, Gugatschka M, European Laryngological Society, Phonosurgery Committee. Vocal fold scars: current concepts and future directions. Consensus report of the Phonosurgery Committee of the European Laryngological Society. Eur Arch Oto-Rhino-Laryngol Off Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 2013; 270:2491–2507. DOI: 10.1007/s00405-013-2498-9

[3]. Coyle SM, Weinrich BD, Stemple JC. Shifts in relative prevalence of laryngeal pathology in a treatment-seeking population. J Voice Off J Voice Found. 2001; 15:424–440. DOI: 10.1016/S0892-1997(01)00043-1

[4]. Hirano S. Current treatment of vocal fold scarring. Curr Opin Otolaryngol Head Neck Surg. 2005; 13:143–147. [PubMed: 15908810]

[5]. Ling C, Li Q, Brown ME, Kishimoto Y, Toya Y, Devine EE, Choi K-O, Nishimoto K, Norman IG, Tseng T, Jiang JJ, et al. Bioengineered vocal fold mucosa for voice restoration. Sci Transl Med. 2015; 7:314ra187.doi: 10.1126/scitranslmed.aab4014

[6]. Graupp M, Bachna-Rotter S, Gerstenberger C, Friedrich G, Fröhlich-Sorger E, Kiesler K, Gugatschka M. The unsolved chapter of vocal fold scars and how tissue engineering could help us solve the problem. Eur Arch Oto-Rhino-Laryngol Off J Eur Fed Oto-Rhino-Laryngol Soc EUFOS Affil Ger Soc Oto-Rhino-Laryngol - Head Neck Surg. 2016; 273:2279–2284. DOI: 10.1007/s00405-015-3668-8

[7]. Hirano S, Mizuta M, Kaneko M, Tateya I, Kanemaru S-I, Ito J. Regenerative phonosurgical treatments for vocal fold scar and sulcus with basic fibroblast growth factor. Laryngoscope. 2013; 123:2749–2755. DOI: 10.1002/lary.24092 [PubMed: 23553343]

[8]. Ohno S, Hirano S, Kanemaru S, Kitani Y, Kojima T, Ishikawa S, Mizuta M, Tateya I, Nakamura T, Ito J. Transforming growth factor β3 for the prevention of vocal fold scarring. Laryngoscope. 2012; 122:583–589. DOI: 10.1002/lary.22389 [PubMed: 22252900]

[9]. Glim JE, van Egmond M, Niessen FB, Everts V, Beelen RHJ. Detrimental dermal wound healing: what can we learn from the oral mucosa? Wound repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2013; 21:648–660. DOI: 10.1111/wrr.12072

[10]. Lorenz HP, Longaker MT, Perkocha LA, Jennings RW, Harrison MR, Adzick NS. Scarless wound repair: a human fetal skin model. Development. 1992; 114:253–259. [PubMed: 1576963]

[11]. Lo DD, Zimmermann AS, Nauta A, Longaker MT, Lorenz HP. Scarless fetal skin wound healing update. Birth Defects Res C Embryo Today. 2012; 96:237–247. DOI: 10.1002/bdrc.21018 [PubMed: 23109319]

[12]. Peake MA, Caley M, Giles PJ, Wall I, Enoch S, Davies LC, Kipling D, Thomas DW, Stephens P. Identification of a transcriptional signature for the wound healing continuum. Wound Repair Regen Off Publ Wound Heal Soc Eur Tissue Repair Soc. 2014; 22:399–405. DOI: 10.1111/wrr.12170
[13]. Chang Z, Kishimoto Y, Hasan A, Welham NV. TGF-β3 modulates the inflammatory environment and reduces scar formation following vocal fold mucosal injury in rats. Dis Model Mech. 2014; 7:83–91. DOI: 10.1242/dmm.013326 [PubMed: 24092879]

[14]. Welham NV, Ling C, Dawson JA, Kendzierski C, Thibeault SL, Yamashita M. Microarray-based characterization of differential gene expression during vocal fold wound healing in rats. Dis Model Mech. 2015; 8:311–321. DOI: 10.1242/dmm.018366 [PubMed: 25592437]

[15]. Thibeault SL, Li W, Gray SD, Chen Z. Instability of extracellular matrix gene expression in primary cell culture of fibroblasts from human vocal fold lamina propria and tracheal scar. Ann Otol Rhinol Laryngol. 2002; 111:8–14. [PubMed: 11800374]

[16]. Hansson SE, Kim J, Johnson BHQ, Bradley B, Breunig MJ, Hematti P, Thibeault SL. Characterization of mesenchymal stem cells from human vocal fold fibroblasts. Laryngoscope. 2010; 120:546–551. DOI: 10.1002/lary.20797 [PubMed: 20131365]

[17]. Hu R, Ling W, Xu W, Han D. Fibroblast-like cells differentiated from adipose-derived mesenchymal stem cells for vocal fold wound healing. PLoS One. 2014; 9:e92676.doi: 10.1371/journal.pone.0092676 [PubMed: 24664167]

[18]. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001; 25:402–408. DOI: 10.1006/meth.2001.1262 [PubMed: 11846609]

[19]. Wiśniewski JR, Zougman A, Nagaraj N, Mann M. Universal sample preparation method for proteome analysis. Nat Methods. 2009; 6:359–362. DOI: 10.1038/nmeth.1322 [PubMed: 19377485]

[20]. Cox J, Hein MY, Luber CA, Paron I, Nagaraj N, Mann M. Accurate proteome-wide label-free quantification by delayed normalization and maximal peptide ratio extraction, termed MaxLFQ. Mol Cell Proteomics MCP. 2014; 13:2513–2526. DOI: 10.1074/mcp.M113.031591 [PubMed: 24942700]

[21]. Vizcaino JA, Csordas A, Del-Toro N, Dianes JA, Griss J, Lavadas I, Mayer G, Perez-Riverol Y, Reisinger F, Ternent T, Xu Q-W, et al. 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2016; doi: 10.1093/nar/gkw880

[22]. Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nat Protoc. 2013; 8:1551–1566. DOI: 10.1038/nprot.2013.092 [PubMed: 23868073]

[23]. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102:15545–15550. DOI: 10.1073/pnas.0506580102 [PubMed: 16199517]

[24]. Mootha VK, Lindgren CM, Eriksson K-F, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstråle M, Laurila E, Houstis N, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003; 34:267–273. DOI: 10.1038/ng1180 [PubMed: 12808457]

[25]. Alipour F, Finnegan EM, Jaiswal S. Phonatory characteristics of the excised human larynx in comparison to other species. J Voice Off J Voice Found. 2013; 27:441–447. DOI: 10.1016/j.jvoice.2013.03.013

[26]. Lee HG, Eun HC. Differences between fibroblasts cultured from oral mucosa and normal skin: implication to wound healing. J Dermatol Sci. 1999; 21:176–182. [PubMed: 10527379]

[27]. Lim X, Tateya I, Tateya T, Muñoz-Del-Río A, Bless DM. Immediate inflammatory response and scar formation in wounded vocal folds. Ann Otol Rhinol Laryngol. 2006; 115:921–929. [PubMed: 17214268]

[28]. Rockey DC, Bell PD, Hill JA. Fibrosis—a common pathway to organ injury and failure. N Engl J Med. 2015; 372:1138–1149. DOI: 10.1056/NEJMr1300575 [PubMed: 25785971]

[29]. Branski RC, Barbieri SS, Weksler BB, Saltman B, Krishna P, Kraus DH, Broadbelt NV, Chen J, Poppas DP, Felsen D. Effects of transforming growth factor-beta1 on human vocal fold fibroblasts. Ann Otol Rhinol Laryngol. 2009; 118:218–226. [PubMed: 19374154]
[30]. Meran S, Thomas D, Stephens P, Martin J, Bowen T, Phillips A, Steadman R. Involvement of hyaluronan in regulation of fibroblast phenotype. J Biol Chem. 2007; 282:25687–25697. DOI: 10.1074/jbc.M700773200 [PubMed: 17611197]

[31]. Liechty KW, Adzick NS, Crombleholme TM. Diminished interleukin 6 (IL-6) production during scarless human fetal wound repair. Cytokine. 2000; 12:671–676. DOI: 10.1006/cyto.1999.0598 [PubMed: 10843743]

[32]. Ohno T, Hirano S, Rousseau B. Age-associated changes in the expression and deposition of vocal fold collagen and hyaluronan. Ann Otol Rhinol Laryngol. 2009; 118:735–741. [PubMed: 19894402]

[33]. Rousseau B, Sohn J, Montequin DW, Tateya I, Bless DM. Functional outcomes of reduced hyaluronan in acute vocal fold scar. Ann Otol Rhinol Laryngol. 2004; 113:767–776. [PubMed: 15535138]

[34]. Chang HY, Chi J-T, Dudoit S, Bondre C, van de Rijn M, Botstein D, Brown PO. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc Natl Acad Sci U S A. 2002; 99:12877–12882. DOI: 10.1073/pnas.162488599 [PubMed: 12297622]

[35]. Sanders MC, Goldstein AL, Wang YL. Thymosin beta 4 (Fx peptide) is a potent regulator of actin polymerization in living cells. Proc Natl Acad Sci U S A. 1992; 89:4678–4682. [PubMed: 1584803]

[36]. Frohn M, Gunne H, Bergman AC, Agerberth B, Bergman T, Boman A, Lidén S, Jörnvall H, Boman HG. Biochemical and antibacterial analysis of human wound and blister fluid. Eur J Biochem. 1996; 237:86–92. [PubMed: 8620898]

[37]. Reyes-Gordillo K, Shah R, Popratiloff A, Fu S, Hindle A, Brody F, Rojkind M. Thymosin-beta4 (Tβ4) blunts PDGF-dependent phosphorylation and binding of AKT to actin in hepatic stellate cells. Am J Pathol. 2011; 178:2100–2108. DOI: 10.1016/j.ajpath.2011.01.025 [PubMed: 21514425]

[38]. Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, Goldstein AL, Kleinman HK. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999; 113:364–368. DOI: 10.1046/j.1523-1747.1999.00708.x [PubMed: 10469335]

[39]. Gospodarowicz D. Localisation of a fibroblast growth factor and its effect alone and with hydrocortisone on 3T3 cell growth. Nature. 1974; 249:123–127. [PubMed: 4368416]

[40]. Cross MJ, Claesson-Welsh L. FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci. 2001; 22:201–207. [PubMed: 11282421]

[41]. McGee GS, Davidson JM, Buckley A, Sommer A, Woodward SC, Aquino AM, Barbour R, Demetriou AA. Recombinant basic fibroblast growth factor accelerates wound healing. J Surg Res. 1988; 45:145–153. [PubMed: 3392988]

[42]. Suehiro A, Hirano S, Kishimoto Y, Rousseau B, Nakamura T, Ito J. Treatment of acute vocal fold scar with local injection of basic fibroblast growth factor: a canine study. Acta Otolaryngol (Stockh.). 2010; 130:844–850. DOI: 10.3109/00016480903426618 [PubMed: 20082571]

[43]. Suehiro A, Hirano S, Kishimoto Y, Tateya I, Rousseau B, Ito J. Effects of basic fibroblast growth factor on rat vocal fold fibroblasts. Ann Otol Rhinol Laryngol. 2010; 119:690–696. [PubMed: 21049855]

[44]. Anai M, Shojima N, Katagiri H, Ogihara T, Sakoda H, Onishi Y, Ono H, Fujishiro M, Fukushima Y, Horike N, Viana A, et al. A novel protein kinase B (PKB)/AKT-binding protein enhances PKB kinase activity and regulates DNA synthesis. J Biol Chem. 2005; 280:18525–18535. DOI: 10.1074/jbc.M505086200 [PubMed: 15753085]

[45]. Jiang P, Enomoto A, Jijiwa M, Kato T, Hasegawa T, Ishida M, Sato T, Asai N, Murakumo Y, Takahashi M. An actin-binding protein Girdin regulates the motility of breast cancer cells. Cancer Res. 2008; 68:1310–1318. DOI: 10.1158/0008-5472.CAN-07-5111 [PubMed: 18316593]

[46]. Ryu J, Galan AK, Xin X, Dong F, Abdul-Ghani MA, Zhou L, Wang C, Li C, Holmes BM, Sloane LB, Austad SN, et al. APPL1 potentiates insulin sensitivity by facilitating the binding of IRS1/2 to the insulin receptor. Cell Rep. 2014; 7:1227–1238. DOI: 10.1016/j.celrep.2014.04.006 [PubMed: 24813896]
[47]. Tomioka H, Nakagami H, Tenma A, Saito Y, Kaga T, Kanamori T, Tamura N, Tomono K, Kaneda Y, Morishita R. Novel anti-microbial peptide SR-0379 accelerates wound healing via the PI3 kinase/Akt/mTOR pathway. PLoS One. 2014; 9:e92597.doi: 10.1371/journal.pone.0092597 [PubMed: 24675668]

[48]. Chen J-C, Lin B-B, Hu H-W, Lin C, Jin W-Y, Zhang F-B, Zhu Y-A, Lu C-J, Wei X-J, Chen R-J. NGF accelerates cutaneous wound healing by promoting the migration of dermal fibroblasts via the PI3K/Akt-Rac1-JNK and ERK pathways. Biomed Res Int. 2014; 2014:547187.doi: 10.1155/2014/547187 [PubMed: 25006578]

[49]. Huang H, Cui W, Qiu W, Zhu M, Zhao R, Zeng D, Dong C, Wang X, Guo W, Xing W, Li X, et al. Impaired wound healing results from the dysfunction of the Akt/mTOR pathway in diabetic rats. J Dermatol Sci. 2015; 79:241–251. DOI: 10.1016/j.jdermsci.2015.06.002 [PubMed: 26091964]

[50]. Cui T, Jimenez JJ, Block NL, Badiavas EV, Rodriguez-Menocal L, Vila Granda A, Cai R, Sha W, Zarandi M, Perez R, Schally AV. Agonistic analogs of growth hormone releasing hormone (GHRH) promote wound healing by stimulating the proliferation and survival of human dermal fibroblasts through ERK and AKT pathways. Oncotarget. 2016; doi: 10.18632/oncotarget.11024

[51]. Yao R, Cao Y, He Y, Lau WB, Zeng Z, Liang Z. Adiponectin attenuates lung fibroblasts activation and pulmonary fibrosis induced by paraquat. PLoS One. 2015; 10:e0125169.doi: 10.1371/journal.pone.0125169 [PubMed: 25945502]

[52]. Ebisawa K, Kato R, Okada M, Sugimura T, Latif MA, Hori Y, Harita Y, Ueda M, Honda H, Kagami H. Gingival and dermal fibroblasts: their similarities and differences revealed from gene expression. J Biosci Bioeng. 2011; 111:255–258. DOI: 10.1016/j.jbiosc.2010.11.014 [PubMed: 21288768]

[53]. Chang DF, Belaguli NS, Iyer D, Roberts WB, Wu S-P, Dong X-R, Marx JG, Moore MS, Beckerle MC, Majesky MJ, Schwartz RJ. Cysteine-rich LIM-only proteins CRP1 and CRP2 are potent smooth muscle differentiation cofactors. Dev Cell. 2003; 4:107–118. [PubMed: 12530967]

[54]. Wall IB, Moseley R, Baird DM, Kipling D, Giles P, Laffaian I, Price PE, Thomas DW, Stephens P. Fibroblast dysfunction is a key factor in the non-healing of chronic venous leg ulcers. J Invest Dermatol. 2008; 128:2526–2540. DOI: 10.1038/jid.2008.114 [PubMed: 18449211]

[55]. Kumar S, Gupta S. Thymosin beta 4 prevents oxidative stress by targeting antioxidant and anti-apoptotic genes in cardiac fibroblasts. PLoS One. 2011; 6:e26912.doi: 10.1371/journal.pone.0026912 [PubMed: 22046407]

[56]. Mizuta M, Hirano S, Ohno S, Tateya I, Kanemaru S-I, Nakamura T, Ito J. Expression of reactive oxygen species during wound healing of vocal folds in a rat model. Ann Otol Rhinol Laryngol. 2012; 121:804–810. [PubMed: 23342553]

[57]. Svitkina TM, Verkhovsky AB, Borisy GG. Plectin sidearms mediate interaction of intermediate filaments with microtubules and other components of the cytoskeleton. J Cell Biol. 1996; 135:991–1007. [PubMed: 8922382]

[58]. Behrens J, Solga R, Ziemann A, Rastetter RH, Berwanger C, Herrmann H, Noegel AA, Clemen C. Coronin 1C-free primary mouse fibroblasts exhibit robust rearrangements in the orientation of actin filaments, microtubules and intermediate filaments. Eur J Cell Biol. 2016; 95:239–251. DOI: 10.1016/j.ejcb.2016.04.004 [PubMed: 27178841]

[59]. Naba A, Clauser KR, Hoersch S, Liu H, Carr SA, Hynes RO. The matrisome: in silico definition and in vivo characterization by proteomics of normal and tumor extracellular matrices. Mol Cell Proteomics MCP. 2012; 11 M111.014647. doi: 10.1074/mcp.M111.014647

[60]. Fukahori M, Chitoso S-I, Sato K, Sueyoshi S, Kurita T, Umeno H, Monden Y, Yamakawa R. Regulation of wound fold mucosa using tissue-engineered structures with oral mucosal cells. PLoS One. 2016; 11:e0146151.doi: 10.1371/journal.pone.0146151 [PubMed: 26730600]

[61]. Takahara K, Kessler E, Biniaminov L, Brusel M, Eddy RL, Juni-Sait T, Shows TB, Green span DS. Type I procollagen COOH-terminal proteinase enhancer protein: identification, primary structure, and chromosomal localization of the cognate human gene (PCOLCE). J Biol Chem. 1994; 269:26280–26285. [PubMed: 7523404]

[62]. Bourhis J-M, Vadon-Le Goff S, Afrache H, Mariano N, Kronenberg D, Thielen N, Moali C, Hulmes DJS. Procollagen C-proteinase enhancer grasps the stalk of the C-propeptide trimer to
[63]. van der Slot AJ, Zuurmond A-M, Bardoeel AFJ, Wijmenga C, Prujs HEH, Sillence DO, Brinckmann J, Abraham DJ, Black CM, Verzijl N, DeGroot J, et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem. 2003; 278:40967–40972. DOI: 10.1074/jbc.M307380200 [PubMed: 12881513]

[64]. Chou C-H, Chang N-W, Shrestha S, Hsu S-D, Lin Y-L, Lee W-H, Yang C-D, Hong H-C, Wei T-Y, Tu S-J, Tsai T-R, et al. Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis. J Biol Chem. 2003; 278:40967–40972. DOI: 10.1074/jbc.M307380200 [PubMed: 12881513]

[65]. Wen M, Men R, Liu X, Yang L. Involvement of miR-30c in hepatic stellate cell activation through the repression of plasminogen activator inhibitor-1. Life Sci. 2016; 155:21–28. DOI: 10.1016/j.lfs.2016.04.034 [PubMed: 27142827]

[66]. Jiang L, Qiu W, Zhou Y, Wen P, Fang L, Cao H, Zen K, He W, Zhang C, Dai C, Yang J. A microRNA-30e/mitochondrial uncoupling protein 2 axis mediates TGF-β1-induced tubular epithelial cell extracellular matrix production and kidney fibrosis. Kidney Int. 2013; 84:285–296. DOI: 10.1038/ki.2013.80 [PubMed: 23515048]

[67]. Bretones G, Delgado MD, León J. Myc and cell cycle control. Biochim Biophys Acta. 2015; 1849:506–516. DOI: 10.1016/j.bbagrm.2014.03.013 [PubMed: 24704206]

[68]. Logan TJ, Jordan KL, Hall D. Altered shape and cell cycle characteristics of fibroblasts expressing the E2F1 transcription factor. Mol Biol Cell. 1994; 5:667–678. [PubMed: 7949423]

[69]. Chong J-L, Tsai S-Y, Sharma N, Opavsky R, Price R, Wu L, Fernandez SA, Leone G. E2F3a and E2F3b contribute to the control of cell proliferation and mouse development. Mol Cell Biol. 2009; 29:414–424. DOI: 10.1128/MCB.01161-08 [PubMed: 19015245]

J Proteomics. Author manuscript; available in PMC 2017 April 12.
Fig. 1.
Comparative cellular characteristics of paired vocal fold fibroblasts (VFF) and oral mucosa fibroblasts (OMF). (A) Representative phase contrast microscopy images from two biological replicates (BR1, BR2); scale bar: 100 μm. (B) Mean cell diameter ± s.e.m. (n = 4) was obtained from trypsinized (i.e. spherical) cells. Data was analyzed by paired t-test; * P ≤ 0.05. (C) Growth curves of fibroblast pairs. (D) Phase contrast microscopy images of 3D spheroid cultures (BR2) were acquired 6 h and 24 h post re-plating; scale bar: 100 μm.
Fig. 2.
Cellular response to pro-fibrotic stimulus. Paired vocal fold fibroblasts (VFF) and oral mucosa fibroblasts (OMF; n = 4) were exposed to TGF-β1 (5 ng/mL) or vehicle (“C”) and expression of (A) α-smooth muscle actin (ACTA2) and (B) interleukin 6 (IL6) was analyzed 24 h and 72 h later. TGF-β1 effects were analyzed by paired t-test.
Fig. 3.
Proteomic profiling of paired vocal fold fibroblasts (VFF) and oral mucosa fibroblasts (OMF). (A) Venn diagram depicting the number of proteins detected solely in VFF, solely in OMF, and in both cell types. (B) Number of robustly detected proteins (≥2 peptide counts (razor + unique)) for each biological replicate (BR1–BR4). (C) Heat map showing log10-transformed normalized LFQ intensity values for three groups: group 1, 520 proteins detected in both cell types; group 2, 45 proteins detected only in VFF; group 3, 9 proteins detected only in OMF. Within each group, proteins are sorted in a decreasing manner.
according to their mean abundance. Clustering tree resulting from unsupervised clustering of samples is shown on top.
Fig. 4.
Cell type-selective protein sets and their significantly enriched Gene Ontology terms. Groups of proteins detected solely in (A) vocal fold fibroblasts (VFF) or (B) oral mucosa fibroblasts (OMF) are depicted as heat map with proteins specified by gene symbol. Right part of panels depicts results of statistical overrepresentation tests performed for the three main Gene Ontology (GO) aspects molecular function, cellular component, and biological process. Grey fields indicate significant (P < 0.05 after Bonferroni correction for multiple testing) overrepresentation of the respective GO term (specified at the bottom).
Fig. 5.
Vulcano plot. Candidate proteins with significantly differential protein abundance (P < 0.05 after Benjamini-Hochberg correction for multiple testing) between paired vocal fold fibroblasts (VFF) and oral mucosa fibroblasts (OMF) are shown in red and specified by gene symbol.
Table 1

Gene sets significantly enriched in vocal fold fibroblasts versus oral mucosa fibroblasts.

| Gene sets database       | Gene sets significantly enriched in VFF versus OMF | FDR q-value | Gene symbols of proteins within core enrichment |
|--------------------------|---------------------------------------------------|-------------|-------------------------------------------------|
| Canonical pathways       | NABA_MATRISOME                                    | 0.0633      | P4HA1, PLOD2, FGF2, COL1A2, P4HA2, S100A2, COL6A1, SERPINH1, P3H1, ANXA3, COL12A1, PCOLCE, COL15A1, COL6A2 |
|                          | NABA_MATRISOME_ASSOCIATED                          | 0.0689      | P4HA1, PLOD2, FGF2, P4HA2, S100A2, SERPINH1, P3H1, ANXA4 |
| KEGG                    | KEGG_REGULATION_OF_ACTIN_CYTOSKELETON             | 0.0440      | MYH10, FGF2, ACTN1, ITGA6, MYH9, PPP1R12A, VCL, ACTN4, ARPC3, RDX, ROCK1, CRK, IQGAP1, ROCK2, ACTB, ARPC4 |
|                          | KEGG_FOCAL_ADHESION                               | 0.0507      | COL1A2, ACTN1, ITGA6, COL6A1, PPP1R12A, VCL, FLNB, ACTN4, PARVA, COL6A2, ROCK1, FLNA, CRK, COL6A3, TNN1, ROCK2, ACTB |
|                          | KEGG_TIGHT_JUNCTION                               | 0.0657      | MYH10, ACTN1, TJP1, EPB41L2, PPP2CB, MYH9, ACTN4 |
| Reactome                | –                                                 | –           | –                                               |
| Hallmark                | HALLMARK_APICAL_JUNCTION                          | 0.0076      | MYH10, NEXN, ACTN1, TJP1, EPB41L2, MYH9, ACTA1, CNN2, VCL, ACTN4, PARVA |
|                         | HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION        | 0.0084      | PLOD2, FGF2, COL1A2, TPM1, FERM12, SERPINH1, TAGLN, DPYSL3, CALU, COL12A1, PCOLCE, COL6A2, FLNA, GJA1 |
| Transcription factor targets | –                                              | –           | –                                               |
| miRNA binding           | TGTTCAC,MIR-30A-5P,MIR-30C,MIR-30D,MIR-30B,MIR-30E-5P | 0.0806      | PTGFRN, MYH10, VAT1, P4HA2, DOCK7, ITGA6, SEC23A, PPP1R12A, HSPA5, CALU, LPP, GFPT2, LIN7C, VAT1L, GJA1 |
| GO biological process   | –                                                 | –           | –                                               |
| GO cellular component   | –                                                 | –           | –                                               |
| GO molecular function   | –                                                 | –           | –                                               |

Distinct gene set databases (column 1) were queried to identify gene sets (column 2) which are significantly (false discovery rate (FDR) q-value <0.1, column 3) VFF-enriched when comparing the protein expression profiles of VFF with OMF. Proteins (specified by gene symbol) detected in
the VFF/OMF samples and having the strongest contribution to the enrichment result (“core enrichment”, as defined by the Gene Set Enrichment Analysis (GSEA) method) are listed in column 4.
Table 2
Gene sets significantly enriched in oral mucosa fibroblasts versus vocal fold fibroblasts.

| Gene sets database | Gene sets significantly (FDR q-value <0.1) enriched in OMF versus VFF | FDR q-value | Gene symbols of proteins within core enrichment |
|--------------------|-------------------------------------------------------------------------|-------------|-----------------------------------------------|
| Canonical pathways  | –                                                                        | –           | –                                             |
| KEGG               | KEgg_SPliceosome                                                        | 0.02613     | DDX39B, PUf60, DDX5, PRPF19, SRSF6, HNRNPU, HNRNP, SRSF1, SRSF2, HNRNPK, HNRNPC, SF3B1, PCBP1, SF3B2 |
| Reactome           | REACTOme_PROCESSing_of_Capped_Intron_Containing_Pre_MRNA                | 0.01592     | DHX9, SRSF6, HNRNPU, HNRNPM, HNRNPL, SRSF1, SRSF2, HNRNPK, HNRNPC, SF3B1, PCBP1, TPR, SF3B2, PTPBP1 |
|                    | REACTOme_MRNA_SPLICING                                                  | 0.03449     | DHX9, SRSF6, HNRNPU, HNRNPM, HNRNPL, SRSF1, SRSF2, HNRNPK, HNRNPC, SF3B1, PCBP1, SF3B2, PTPBP1 |
|                    | REACTOme_MRNA_PROCESSING                                                | 0.01884     | DHX9, SRSF6, HNRNPU, HNRNPM, HNRNPL, SRSF1, SRSF2, HNRNPK, HNRNPC, SF3B1, PCBP1, TPR, SF3B2, PTPBP1 |
|                    | REACTOme_Metabolism_of_Lipids_and_Lipoproteins                          | 0.08798     | ACLY, HMGCS1, ME1, |

J Proteomics. Author manuscript; available in PMC 2017 April 12.
| Gene sets database         | Gene sets significantly (FDR q-value <0.1) enriched in OMF versus VFF | FDR q-value | Gene symbols of proteins within core enrichment |
|---------------------------|---------------------------------------------------------------------|-------------|-------------------------------------------------|
| Hallmark                  | HALLMARK_E2F_TARGETS                                               | <10-E4      | CSE1L, PA2G4, SYNCRIP, RANBP1, SRSF1, PCNA, STMN1, PAICS, RBBP7, SMC3, MCM3, LMNB1, MCM6, H2AFX, RPA1, LBR |
|                           | HALLMARK_G2M_CHECKPOINT                                           | <10-E4      | SFQ, HNRNPU, NCL, SYNCRIP, SRSF1, BUB3, STMN1, NUMA1, G3BP1, SMC2, MCM3, LMNB1, MCM6, H2AFX, LBR |
|                           | HALLMARK_MYC_TARGETS_V1                                            | 0.05351     | HSP90AB1, CCT4, PSMC6, YWHAE, RRM1, CCT7, PSMA4, CCT3, RAN, RPS5, KPNB1, PABPC4, FAM120A, RUVBL2, IMPDH2, DUT, PSMD3, HNRNPU, CCT5, TARDBP, PA2G4, PSMMA1, SYNCRIP, RANBP1, SRSF1, SERRBP1, PCNA, HNRNPC, BUB3, CBX3, CNBP, PCBP1, G3BP1, MCM6 |
| Gene sets database | Gene sets significantly (FDR q-value <0.1) enriched in OMF versus VFF | FDR q-value | Gene symbols of proteins within core enrichment |
|--------------------|-------------------------------------------------|-------------|-----------------------------------------------|
| Transcription factor targets | VSE2F1_Q4_01 | 0.00835 | KPNB1, RPS19, HIST1H1D, IMPDH2, NCL, RANBP1, SRSF1, SERBP1, PCNA, STMN1, CNBP, SMC3, SMC2, MCM3, DDX17, PTMA, MCM6, UCHL1 |
|                      | VSE2F_Q3_01 | 0.03749 | KPNB1, RPS19, HIST1H1D, NCL, RANBP1, SRSF1, SERBP1, PCNA, STMN1, RALY, SMC3, NUMA1, SMC2, MCM3, DDX17, PTMA, MCM6, UCHL1 |
|                      | VSE2F_Q4_01 | 0.03923 | KPNB1, RPS19, HIST1H1D, IMPDH2, NCL, RANBP1, SRSF1, SERBP1, PCNA, STMN1, CNBP, SMC3, SMC2, MCM3, DDX17, PTMA, MCM6, UCHL1 |
| miRNA binding       | –                               | –           | –                                      |
| GO biological process | CELL_PROLIFERATION_GO_0008283 | 0.02559 | FSCN1, CSE1, PA2G4, |
| Gene sets database                  | Gene sets significantly (FDR q-value < 0.1) enriched in OMF versus VFF | FDR q-value | Gene symbols of proteins within core enrichment |
|-------------------------------------|---------------------------------------------------------------------|-------------|-------------------------------------------------|
| RNA_SPLICING                       |                                                                     | 0.03236     | PCNA, BUB3, NUDC, RBBP7, KHDRBS1, CCDC88A, APPF1, PRDX1 |
| GO cellular component              | NUCLEAR_PART                                                        | <10-E4      | HNRNPU, PSMA1, HNRNPM, HNRNPL, SNRP70, HNRNPC, RALY, IVNS1ABP, SF3B2, PTBP1 |
| RIBONUCLEOPROTEIN_COMPLEX           |                                                                     | 0.00929     | HNRNPU, PSMA1, HNRNPM, HNRNPL, SNRP70, HNRNPC, RALY, IVNS1ABP, SF3B2, PTBP1 |
| NUCLEUS                            |                                                                     | 0.01046     | DUT, DDX19B, HNRNPU, RPS3A, TARDBP, PARP1, THRAP3, IPO5, NCL, CSE1L, TNPO1, PA2G4, PSMA1, SYNCRIPT, RANBP1, HNRNPM, HNRNPL, SNRP70, HNRNPC, PTRF, HNRNPC, MATR3, NONO, CBX3, EHD4, TPR, RALY |
| Gene sets database | Gene sets significantly (FDR q-value <0.1) enriched in OMF versus VFF | FDR q-value | Gene symbols of proteins within core enrichment |
|--------------------|---------------------------------------------------------------|-----------|-------------------------------------------------|
| NUCLEAR_ENVELOPE   |                                                              | 0.01540   | SMC3, NUMA1, IVNS1ABP, G3BP1, SMC2, SF3B2, KHDRBS1, MCM3, DDX17, LMNB1, PTBP1, PTMA, H2AFX, RPA1, DHCR7, ACTL6A, APPL1, NUP160, LBR |
| NUCLEAR_LUMEN      |                                                              | 0.01985   | SRP68, LYR, RPS19, RUVBL2, PARP1, THRAP3, NCL, HNRNPL, HNRNPK, SMC3, IVNS1ABP, PTBP1, RPA1, ACTL6A, APPL1 |

GO molecular function    DNA_BINDING                                     0.02572   HNRNPU, TARDBP, PARP1, PA2G4, CNBP, PCB1, KHDRBS1, MCM3, RPA1, LBR |

Distinct gene set databases (column 1) were queried to identify gene sets (column 2) which are significantly (false discovery rate (FDR) q-value <0.1, column 3) OMF-enriched when comparing the protein expression profiles of VFF with OMF. Proteins (specified by gene symbol) detected in the VFF/OMF samples and having the strongest contribution to the enrichment result (“core enrichment”, as defined by the Gene Set Enrichment Analysis (GSEA) method) are listed in column 4.